{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:18:52Z","timestamp":1789611532976,"version":"build-2803163510"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Knight Therapeutics"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study aims to evaluate the cost-utility and the budgetary impact of isavuconazole compared to voriconazole in patients with suspected invasive aspergillosis (IA) from the perspective of the Brazilian supplementary health system (SHS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>In this model, a decision tree was developed and included patients with possible IA. Efficacy parameters were extracted from the clinical studies. Drug acquisition, hospitalization costs and adverse events were also collected. Alternative 3- and 10-year time horizon scenarios were used. In addition, deterministic and probabilistic sensitivity analyses were simulated. A budget impact analysis of isavuconazole versus voriconazole was performed, assuming a time horizon of 5 years. In addition, sensitivity analyses were conducted to assess the robustness of the model. Results are reported in Brazilian Real (BRL), year values 2022.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The economic analysis of the base case showed that isavuconazole is associated with a saving of 95,174.00 BRL per patient compared to voriconazole. All other simulated scenarios showed that isavuconazole is dominant versus comparators when considering a willingness to pay 40,688.00 BRL\/Quality-Adjusted Life Years (QALY). The results were considered robust by the sensitivity analyses. The budget impact analysis showed that the incorporation of isavuconazole generates savings to the SHS, compared to voriconazole, of approximately 20.5 million BRL in the first year. This reaches about 54 million BRL in the fifth incorporation year, considering the market penetration of 20% in the first year, and 50% in the fifth year.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Compared with voriconazole, isavuconazole is regarded as a dominant treatment strategy for patients with suspected IA and generates savings for the SHS.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0299056","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T18:26:28Z","timestamp":1709317588000},"page":"e0299056","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic and budgetary impact evaluation of isavuconazole (Cresemba\u00ae) versus voriconazole (Vfend\u00ae) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system"],"prefix":"10.1371","volume":"19","author":[{"given":"Gisele Lemes Veiga","family":"Araujo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0463-505X","authenticated-orcid":true,"given":"Laura","family":"Murta Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2991-3084","authenticated-orcid":true,"given":"Vinicius","family":"Ponzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime Luis","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"2","key":"pone.0299056.ref001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14656566.4.2.147","article-title":"Antifungal pharmacotherapy for invasive mould infections","volume":"4","author":"JC Gallagher","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"pone.0299056.ref002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"M Nucci","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"pone.0299056.ref003","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach","volume":"7","author":"MD Bergamasco","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"4","key":"pone.0299056.ref004","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: Mechanism of action, clinical efficacy, and resistance","volume":"6","author":"M Ellsworth","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"1","key":"pone.0299056.ref005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12879-019-3683-2","article-title":"Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden","volume":"19","author":"L Floros","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0299056.ref006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/myc.13189","article-title":"The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain","volume":"64","author":"JR Azanza","year":"2021","journal-title":"Mycoses"},{"issue":"5","key":"pone.0299056.ref007","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14737167.2021.1981862","article-title":"Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada","volume":"22","author":"C Beauchemin","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10020","key":"pone.0299056.ref008","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"JA Maertens","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"pone.0299056.ref009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"F Tissot","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"pone.0299056.ref010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"AJ Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"pone.0299056.ref011","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12324","article-title":"Impaired healthrelated quality of life in acute myeloid leukemia survivors: a single-center study","volume":"93","author":"A Leunis","year":"2014","journal-title":"Eur J Haematol"},{"issue":"7","key":"pone.0299056.ref012","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010","volume":"20","author":"D Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"pone.0299056.ref013","unstructured":"ANVISA. Bula Voriconazol Gen\u00e9rico. [Cited 2023 June 7]. https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?nomeProduto=VORICONAZOL"},{"key":"pone.0299056.ref014","unstructured":"ANVISA. Bula Vfend. [Cited 2023 June 7]. https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?nomeProduto=VFEND"},{"issue":"7","key":"pone.0299056.ref015","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"FM Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pone.0299056.ref016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"G Chamilos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"pone.0299056.ref017","unstructured":"FDA clinical review. NDA 207\u2013501: Cresemba\u00ae (Isavuconazonium) for Injection. NDA 207\u2013500: Cresemba\u00ae (Isavuconazonium) Capsules. 2014."},{"key":"pone.0299056.ref018","unstructured":"CMED. C\u00e2mara de Regula\u00e7\u00e3o do Mercado de Medicamentos 2022. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos\/cmed\/precos"},{"key":"pone.0299056.ref019","unstructured":"UNIDAS 2022 UNIDAS\u2014Uni\u00e3o Nacional Institui\u00e7\u00f5es Autogest\u00e3o em Sa\u00fade. https:\/\/unidas.org.br\/restrito\/documentos\/index.php\/download\/relatorio_2022"},{"key":"pone.0299056.ref020","unstructured":"Banco Central do Brasil. Calculadora de juros. [Cited 2023 June 7]. https:\/\/www3.bcb.gov.br\/CALCIDADAO\/publico\/exibirFormFinanciamentoPrestacoesFixas.do?method=exibirFormFinanciamentoPrestacoesFixas"},{"key":"pone.0299056.ref021","unstructured":"CBHPM. Classifica\u00e7\u00e3o Brasileira Hierarquizada de Procedimentos M\u00e9dicos 2022. https:\/\/amb.org.br\/noticias\/chegou-a-cbhpm-2022\/"},{"issue":"14","key":"pone.0299056.ref022","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"TJ Walsh","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0299056.ref023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1600-0609.2007.00850.x","article-title":"A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK","volume":"78","author":"K Bruynesteyn","year":"2007","journal-title":"Eur J Haematol"},{"key":"pone.0299056.ref024","unstructured":"CONITEC. Diretrizes Metodol\u00f3gicas para Estudos de Avalia\u00e7\u00e3o Econ\u00f4mica de tecnologias em Sa\u00fade, publicada pelo Minist\u00e9rio da Sa\u00fade. [Cited 2023 June 7]. https:\/\/www.gov.br\/conitec\/pt-br\/assuntos\/avaliacao-de-tecnologias-em-saude\/diretrizes-metodologicas"},{"key":"pone.0299056.ref025","unstructured":"IBGE. Proje\u00e7\u00e3o da popula\u00e7\u00e3o por sexo e idades simples, em 1\u00ba de julho\u20142010\/2060. [Cited 2023 June 7]. https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fftp.ibge.gov.br%2FProjecao_da_Populacao%2FProjecao_da_Populacao_2018%2Fprojecoes_2018_populacao_idade_simples_2010_2060_20201209.xls&wdOrigin=BROWSELINK"},{"issue":"3","key":"pone.0299056.ref026","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/myc.12427","article-title":"The burden of serious human fungal infections in Brazil","volume":"59","author":"J Giacomazzi","year":"2016","journal-title":"Mycoses"},{"issue":"12S","key":"pone.0299056.ref027","article-title":"Economic Evaluation of Isavuconazole Versus Voriconazole for the Treatment of Patients with Possible Invasive Aspergillosis in the Brazilian Private Healthcare System","volume":"25","author":"GLV Araujo","year":"2022","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"pone.0299056.ref028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1439-0507.2008.01525.x","article-title":"Nephrotoxicity in the setting of invasive fungal diseases","volume":"51","author":"AJ Ullmann","year":"2008","journal-title":"Mycoses"},{"issue":"1","key":"pone.0299056.ref029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.riam.2012.09.003","article-title":"Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?","volume":"30","author":"FF Tuon","year":"2013","journal-title":"Rev Iberoam Micol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T18:26:50Z","timestamp":1709317610000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299056"}},"subtitle":[],"editor":[{"given":"Felix","family":"Bongomin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299056","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}